Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) CEO Sushil Patel sold 49,026 shares of the stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $21.60, for a total transaction of $1,058,961.60. Following the completion of the transaction, the chief executive officer owned 659,125 shares of the company’s stock, valued at $14,237,100. This represents a 6.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Replimune Group Price Performance
Shares of NASDAQ:REPL opened at $19.23 on Friday. The company has a 50 day moving average of $15.22 and a 200-day moving average of $10.30. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59. Replimune Group, Inc. has a twelve month low of $1.50 and a twelve month high of $23.54.
Replimune Group (NASDAQ:REPL – Get Free Report) last released its earnings results on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.24. On average, research analysts expect that Replimune Group, Inc. will post -2.38 earnings per share for the current year.
Analysts Set New Price Targets
A number of research firms have recently issued reports on REPL. JPMorgan Chase & Co. increased their price target on shares of Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective on the stock in a research note on Friday, August 7th. Leerink Partners increased their price objective on Replimune Group from $19.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. Finally, Wolfe Research raised Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Replimune Group currently has a consensus rating of “Moderate Buy” and an average target price of $18.17.
Read Our Latest Analysis on REPL
Institutional Investors Weigh In On Replimune Group
Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Replimune Group in the second quarter valued at about $99,171,000. Montanova Capital LLC increased its position in shares of Replimune Group by 4.0% during the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after purchasing an additional 168,000 shares in the last quarter. Marshall Wace LLP bought a new position in Replimune Group during the 3rd quarter valued at about $50,516,000. Opaleye Management Inc. bought a new position in Replimune Group during the 2nd quarter valued at about $15,332,000. Finally, Dimensional Fund Advisors LP boosted its position in Replimune Group by 1.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company’s stock valued at $8,719,000 after buying an additional 20,742 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.
More Replimune Group News
Here’s some of the latest news about REPL:
- Positive Sentiment: A report cited potential upside implied by analyst price targets and improving earnings-estimate revisions. Price targets are not reliable predictors on their own. Zacks analyst expectations
- Positive Sentiment: An earnings-call recap highlighted a rapid TUDRIQEV launch, a potentially favorable commercial development for the company. Earnings-call recap
- Neutral Sentiment: The CEO, CFO, chief accounting officer and another insider sold a combined 82,081 shares at $21.60, but filings say the sales covered tax withholding on vested equity awards. Each retained a substantial holding, tempering the negative signal. Insider transaction report
Replimune Group Company Profile
Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.
See Also
- Five stocks we like better than Replimune Group
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
